



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 :

C07H 15/12, C12N 5/00  
G02F 1/11, C12N 15/00

A1

(11) International Publication Number:

WO 90/07517

(43) International Publication Date:

12 July 1990 (12.07.90)

(21) International Application Number: PCT/US89/05859

(22) International Filing Date: 26 December 1989 (26.12.89)

(30) Priority data:

289,561

23 December 1988 (23.12.88) US

(60) Parent Application or Grant

(63) Related by Continuation

US

Filed on

289,561 (CIP)

23 December 1988 (23.12.88)

(71) Applicant (for all designated States except US): THE SALK  
INSTITUTE FOR BIOLOGICAL STUDIES [US/US];  
10010 North Torrey Pines Road, La Jolla, CA 92037  
(US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): EVANS, Ronald, Mark  
[US/US]; 8615 La Jolla Scenic Drive, La Jolla, CA  
92037 (US). HOLLENBERG, Stanley, Mark [US/US];  
240 23rd Street, Del Mar, CA 92014 (US). ORO, An-  
thony, Eugene [US/US]; 4812 Mount Etna Drive, San  
Diego, CA 92117 (US).(74) Agents: WATT, Phillip, H. et al.; Fitch, Even, Tabin &  
Flannery, Room 900, 135 South LaSalle Street, Chicago,  
IL 60603 (US).(81) Designated States: AT (European patent), AU, BE (Euro-  
pean patent), CH (European patent), DE (European pa-  
tent), ES (European patent), FR (European patent), GB  
(European patent), IT (European patent), JP, LU (Euro-  
pean patent), NL (European patent), SE (European pa-  
tent), US.

## Published

*With international search report.**Before the expiration of the time limit for amending the  
claims and to be republished in the event of the receipt of  
amendments.*

(54) Title: RECEPTOR TRANSCRIPTION-REPRESSION ACTIVITY COMPOSITIONS AND METHODS



α168 Repression    MTV Activation

-Steroid	+Steroid	-Steroid	+Steroid
*	*	**	**
*	100	**	100
*	*	**	**
11 ± 2	11 ± 2	15	15
62 ± 7	62 ± 7	10	10
*	60 ± 7	**	150
*	*	**	**

## (57) Abstract

Disclosed is an analysis of domains of receptors of the steroid/thyroid hormone superfamily, and particularly of the glucocorticoid receptor, to identify requirements for the trans-acting transcriptional repression activities of the receptors. Based on the analysis, certain novel receptor analogs are provided, as are various novel DNAs; expression vectors, cells and transgenic animals as well as novel methods of using trans-acting transcription-repressing analogs of the receptors in various applications. These applications include gene therapy, screening of cells in culture or transgenic animals for compositions effective to treat various diseases due to inability to properly respond to hormones of the steroid or thyroid hormone group, and screening of cells in culture for ligands that are capable, upon binding to one of the receptors, to activate its trans-acting transcription activating and trans-acting transcription-repressing activities.

***FOR THE PURPOSES OF INFORMATION ONLY***

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

RECEPTOR TRANSCRIPTION-REPRESSION ACTIVITY  
COMPOSITIONS AND METHODS

Related Applications

Receptors, assay methods, and other subject matter pertinent to the subject matter of the present  
5 specification are described in the following patent applications, which are incorporated herein by reference: PCT International Publication No. WO 88/03168; European Patent Application Publication No. 0325849; and PCT International Application No. US89/05419, filed  
10 November 29, 1989 (see Hollenberg and Evans, Cell 55, 899 (1988))..

Field of the Invention

The present invention relates to the trans-acting  
15 transcription-repression activity of hormone receptors of the steroid/thyroid hormone receptor superfamily. More particularly, it relates to the identification and characterization of amino acids and amino acid sequences in such hormone receptors, especially the steroid hormone  
20 receptors and including those of the human species, that are responsible for such repressor activity, receptor analogs based on such identification and characterization, and preparation and use of such receptor analogs.

Receptor analogs, which have been discovered to  
25 have transcription-repression activity greater than that of the corresponding, naturally occurring receptor, and DNAs from which such analogs can be expressed in mammalian cells, may advantageously be employed to provide model cellular and transgenic-animal systems of  
30 diseases, including human diseases, associated with the inability to respond properly to the hormone, which is the natural ligand of the naturally occurring receptor. These model systems, in turn, may be employed advantageously to screen for compositions that are  
35 effective in treating such diseases.

The receptor analogs identified in connection with the invention, and DNAs from which such analogs can be

expressed in mammalian cells, may also find use in gene therapy to treat diseases associated with the inability to respond properly to the hormone, which is the natural ligand of the naturally occurring receptor corresponding  
5 to the analog.

Finally, the receptor analogs, whose transcription-repression activity is ligand- (e.g., hormone-) dependent, DNAs from which such analogs can be expressed and cells in which such DNAs are expressed, can be  
10 employed in functional assay systems, such as those described in the aforementioned patent applications, to screen for ligands that are effective in inducing the activities of the naturally occurring receptor corresponding to the analog.

15

#### Background of the Invention

The applications cited supra disclose, inter alia, the characterization and preparation of various hormone and hormone-like receptors, including the glucocorticoid, mineralocorticoid, thyroid hormone, and retinoic acid  
20 receptors, and analogs of such receptors. These receptors are members of the steroid/thyroid hormone superfamily of receptors. This superfamily is now known, from numerous publications in the art which have  
25 described details of such receptors and DNAs that encode them, to include also, inter alia, the estrogen receptor, the progesterone receptor, and the vitamin D3 receptor.

In PCT International Application No. US89/05419 (corresponding to United States Patent Application Serial  
30 No. 278,614, filed on 30 November 1988) are disclosed hormone or hormone-like receptor analogs, for example, analogs of steroid receptors, thyroid hormone receptors, and retinoic acid receptors, including those of the human species, where advantage is provided by enhancement, over  
35

that of the corresponding naturally occurring receptor,  
of the trans-acting, transcription-activation or  
transcription-enhancement activity. Such enhancement is  
provided by changes in domains, of the naturally  
5 occurring receptors, that were found to be necessary for  
the transcription-activation or transcription-enhancement  
activities of the receptors.

It is known, for example, that the glucocorticoid  
receptor belongs to the large, steroid/thyroid hormone  
10 superfamily of ligand-dependent, transcription factors  
that have diverse roles in homeostasis, reproduction,  
development, growth, function of the immune system and  
function of the central and peripheral nervous systems,  
among others. Comparison of complementary DNAs encoding  
15 receptors of this superfamily, as well as mutational  
analyses of these DNAs, have identified certain  
functional domains within the receptor molecules  
responsible respectively for DNA binding, hormone binding  
and nuclear localization. See Evans, et al., Science  
20 240, 889 (1988) for a review of this subject matter. In  
the case of the glucocorticoid receptor, the so-called  
DNA binding domain spans some sixty-six amino acids and  
is highly conserved among various species and this domain  
has been found to be required in order to activate  
25 transcription. See Hollenberg, et al., Cell 49, 39  
(1987), Miesfeld, et al., Science 236, 423 (1987),  
Danielsen, et al., Mol.Endo 1, 816 (1987), Kumar, et al.,  
Cell 51, 941 (1987), Gronemeyer, EMBO J. 6, 3985 (1987),  
and Waterman, et al., Mol.Endo 2, 14 (1988). This region  
30 has been found to contain nine invariant cysteine  
residues and, although the contribution of each cysteine  
residue to overall function as well as the actual  
structure of this domain, remain unknown, it has been  
proposed that these cysteine residues coordinate two zinc  
35 ions to form two DNA-binding, so-called "zinc-finger,"

domains which result in a tertiary structure thought responsible for localization and binding of the glucocorticoid receptor to the requisite DNA site.

Similar zinc-finger structures are present in other  
5 receptors of the steroid/thyroid hormone receptor superfamily. See Klug, et al., Tr.Biochem.Sci 12, 464 (1987), Bens, et al., Cell 52, 1 (1988), and Evans, supra.

In a location nearer the carboxyl-terminal end of the receptor molecule, distal from the DNA binding region  
10 of the molecule, is the so-called ligand-binding domain. In the absence of ligand (e.g., hormone or hormone-analog which complexes with the receptor at the ligand-binding domain), the ligand-binding domain functions to block transcription-affecting activity of the receptor. Thus,  
15 presence of the requisite hormone relieves the inhibition of the receptor to such activity. Deletion of the ligand-binding domain from a receptor of the steroid/thyroid hormone superfamily has been found to produce a hormone-independent transcription activator. See  
20 Godowski, et al., Nature 325, 365 (1987), Hollenberg, et al., supra, Kumar, et al., supra, Danielsen et al., supra, and Adler et al., Cell 52, 685 (1988).

In contrast to these two domains, the domain of a receptor lying towards the amino-terminal region from the  
25 DNA binding domain is poorly understood both as to structure and function. This domain nearer the amino-terminus is extremely variable both in size and in composition among the various receptors. See Evans, supra. The domain may contribute to the heterogeneity of  
30 receptor function, despite the overall similarity otherwise of the receptors of the superfamily. See Kumar et al., supra, and Tora et al., 333, 185 (1988).

Despite extensive analysis, some of which has been reported in the scientific literature, the region(s) that  
35 are responsible (in conjunction with the DNA binding of

the receptor) for the transcription activation or enhancement caused by a receptor remains poorly characterized. Transcription-activation (or transcription-enhancement) domains can be defined as regions of a receptor molecule that, when combined with the DNA binding functional domain, increase productive transcription initiation by RNA polymerases at a promoter affected by the receptor. See Sigler, Nature 333, 210 (1988), Brent et al., Cell 43, 729 (1985), Hope et al., Cell 46, 885 (1986), Ma et al., Cell 48, 847 (1987), Ma et al., Cell 51, 113 (1987), Lech et al., Cell 52, 179 (1988), and Hope et al., Nature 333, 635 (1988).

Previous research on the human glucocorticoid receptor by linker scanning mutagenesis identified two regions outside of the DNA binding region having a role in transcription activation. These regions were defined as  $\tau_1$  and  $\tau_2$ . Giguere et al., Cell 46, 645 (1986). Further research from these laboratories has also resulted in the report of a co-localization of transcription-activation and DNA-binding functions. See Hollenberg et al., supra, Miesfeld, et al., supra, Danielsen et al., supra, and Waterman et al., supra. As a composite, this research has given rise merely to a picture, for a receptor of the steroid/thyroid hormone superfamily, that is becoming increasingly modular, with discrete domains, each contributing to the functions of ligand-binding, DNA-binding and "trans-activation" (by which is meant, herein, trans-acting transcription-activation (or enhancement)). However, the picture based upon extant literature does not adequately portray the dynamic nature of the activities of the steroid/thyroid hormone receptors and how the various domains participate in the cascade of events initiated by ligand-binding and consummated by promoter-specific trans-activation.

Further, although previous research has identified functional "domains", there has been little systematic effort to identify amino acids and sequences thereof in the receptor molecules that correspond to these domains and contribute to the activities identified for the domains. Thus, the previous identification of steroid receptor trans-activation regions resulted only from a demonstrated loss of activity via deletion or insertional mutagenesis, but in no case have the properties of the regions themselves been confirmed in assays that reflect a dominant gain of function. See also Ptashne, Nature 335, 683 (1988).

Thus, Godowski et al., Science 241, 812 (1988), report results that show that the glucocorticoid receptor contains at least one "enhancement domain" other than that overlapping the segment of DNA to which the receptor binds (i.e., the glucocorticoid response element or "GRE") and that this second domain occupies a region near the receptor amino-terminus. Similarly, Webster et al., Cell 54, 199 (1988) report on an inducible transcription activation function of the estrogen and glucocorticoid receptors, and these researchers speculate that the relative positions of the ligand-binding and DNA-binding domains are not important for the trans-activation by the receptor. Yet, these researchers admit that they have no definition of the exact location and nature of what they call the "hormone-inducible activating domain" responsible for this inducible transcription activation function and they provide no characterization of the domain and no description of how, in molecular terms, it might contribute to trans-activation.

As a starting point for the present invention, Giguere et al., supra, demonstrated loss of activity in mutants of the glucocorticoid receptor, provided by DNAs resulting from random site-mutagenesis at several



locations in a cDNA encoding the receptor. The loss of activity observed by Giguere et al. in this study was in an assay measuring transcription activity from a promoter operatively associated with a GRE so that transcription  
5 from the promoter was affected by glucocorticoid hormone receptor binding to the GRE. As a follow-up, Hollenberg et al., supra, deleted regions in the receptor molecule, again demonstrating overall loss of transcription activity induced by such removal of stretches of amino  
10 acids.

In PCT International Application No. US89/05419, filed November 29, 1989, and corresponding to United States Patent Application Serial No. 278,614, filed November 30, 1988, as well as Hollenberg and Evans,  
15 supra, domain(s) responsible for trans-activation ("trans-activation" domains, i.e., domains responsible for the trans-acting transcription-activating activity of an hormone receptor at a promoter whose transcription activity is affected by the receptor) was (were)  
20 identified and characterized, and the characterization of such domain(s) in respect of amino acid composition and sequence was developed, to explore the functional interaction of the domain(s) with both the DNA-binding and ligand-binding domains of a given receptor, and  
25 finally, to exploit such knowledge to provide receptor analogs with increased trans-activating activity in comparison with that of the corresponding, naturally occurring receptor.

The present invention makes further use of the  
30 information provided by the invention disclosed in PCT International Application No. US89/05419 and Hollenberg and Evans, supra.

The human glucocorticoid receptor (hGR) has served as a prototype, model receptor for studying regulation of  
35 gene transcription by receptors of the steroid/thyroid

hormone superfamily. The DNA-binding and ligand-binding functional domains of the hGR were first defined and the corresponding domains of other members of the superfamily identified in part on the basis of the results with the  
5 hGR. Further, it has been found that these DNA-binding and ligand-binding domains are modular in that, for example, the ligand-binding domain of a first hormone receptor (e.g., hGR) may be swapped with a ligand-binding domain of a second hormone receptor (e.g., hTR (human  
10 thyroid hormone receptor)) to produce a hybrid receptor the DNA-binding domain of which retains specificity for its cognate response element (GRE) in DNA, but which trans-activates only in the presence of the hormone (thyroid hormone, in this case) specific for the second  
15 receptor. Thus, reference herein to the "naturally occurring" receptor corresponding to a receptor analog of the invention means the naturally occurring receptor with the DNA-binding domain that is closest in primary sequence to the DNA-binding domain of the analog.

20 While trans-activation by the hGR (and other receptors of the steroid/thyroid hormone receptor superfamily) has been examined and elucidated in considerable detail, relatively little is known about "trans-repression" by the hGR or other receptors of the  
25 superfamily (i.e., trans-acting repression of transcription from a promoter, transcription from which is subject to repression by such a receptor).

Among their many effects in development and the reproductive, hepatic, metabolic, nervous and other  
30 systems, glucocorticoid hormones help determine neural crest cell fate in the developing sympathoadrenal system in part by repressing the induction of neural-specific genes (See Stein et al., Dev Bio 127, 316 (1988) and Anderson et al, Cell 47, 1079 (1986).) Also

glucocorticoid hormones modulate the hypothalamic-pituitary-adrenal axis by inhibiting second messenger-induced peptide hormone induction. Recently, Akerblom et al. (Science 241, 350 (1988)) showed that the hGR  
5 negatively regulates (i.e., represses transcription from) the cAMP-inducible alpha glycoprotein hormone promoter in a steroid- and DNA-binding dependent manner. Wild-type expression is initiated by transcription from a promoter of just 168 base pairs (termed alpha168). Basal  
10 expression of alpha glycoprotein hormone in placental cells is mediated by factors bound to a 36 base pair palindromic cyclic AMP response element (CRE) cooperating with proteins binding to a 25 base pair tissue-specific element (TSE). Expression may be further enhanced  
15 through the CRE by the elevation of intracellular cyclic AMP levels. The hGR represses both the basal and cAMP enhanced transcription in a glucocorticoid-dependent fashion. The transacting elements to which the hGR binds have been defined and are related to the consensus GRE  
20 sequence that has been defined in studies of trans-activation by the hGR. Similar research is reported by Sakai, et al., Genes and Development 2, 1144 (1988).

It is an object of the present invention to provide  
25 novel hormone or hormone-like receptor analogs that have trans-acting, transcription-repressing activity, at promoters whose transcription activity is capable of being repressed by the corresponding, native (i.e., naturally occurring) receptor. The novel receptor  
30 analogs are characterized in that they possess domains at their C-termini that differ in certain ways from the corresponding domains in the corresponding, native receptors.

It is a further object of the invention to provide  
35 novel, model, cellular and transgenic-animal systems of

diseases, including human diseases, associated with the inability to respond properly to the hormone, which is the natural ligand of a naturally occurring receptor. It is still a further object of the invention to use  
5 these model systems to screen for compositions that are effective in treating such diseases. These cellular and transgenic-animal, model systems employ certain receptor analogs which have been found to have certain trans-repression-related activities, particularly  
10 transcription-repression activity greater than that of the corresponding, naturally occurring receptor, and DNAs of the invention, from which such analogs can be expressed in mammalian cells. Novel cells of the invention, including cells in novel transgenic animals of  
15 the invention which comprise novel cells of the invention, in which such receptor analogs are expressed will respond aberrantly to the hormone corresponding to the receptor analog because trans-repressing activities by the receptors (including the analog) for the hormone  
20 in the cells will aberrantly dominate trans-activating activities by such receptors.

It is a further object of the invention to use receptor analogs, which have been identified to have certain trans-repression activities, and DNAs of the  
25 invention, from which such analogs can be expressed in mammalian cells, in gene therapy to treat diseases associated with the inability to respond properly to the hormone, which is the natural ligand of the naturally occurring receptor corresponding to the analog. The  
30 effect of having the receptor analog in a subset of the cells of a mammal (including a human) treated by such gene therapy, would be to modulate the response of the mammal to the hormone to a more nearly normal response.

The invention has as still another object novel,  
35 functional assay systems, which employ the receptor analogs of the invention, whose transcription-repression

activity is ligand-(e.g., hormone-)dependent, novel DNAs of the invention, from which such analogs can be expressed, and novel cells of the invention, in which such DNAs are expressed, to screen for ligands that are  
5 effective in inducing the activities of the naturally occurring receptor corresponding to the analogs. Such functional assay systems to screen for such ligands are described in PCT International Publication No. WO 88/03168 and European Patent Application Publication No. 0 325 849.

10

#### Summary of the Invention

The present invention is based upon an analysis of the structural requirements of the hGR for effecting trans-repression. This analysis has revealed that,  
15 although deletion of portions of the N-terminus of a hormone receptor (the hypervariable region) may affect transcription repressing activity, potent trans-repressing receptors may be made which lack the entire N-terminal domain. The DNA binding domain is necessary,  
20 but not sufficient, for transcription-repressor activity. Surprisingly, however, a receptor analog having practically any polypeptide at its C-terminus which is capable of providing sufficient molecular volume will have transcription repressing activity, although  
25 preferably the C-terminal domain of a receptor analog employed in accordance with the invention includes a modified ligand-binding domain of a receptor of the steroid/thyroid hormone receptor superfamily, as described herein. Thus, a receptor analog comprising  
30 such a C-terminal domain, including one which is not capable of ligand-binding, fused to a DNA-binding domain is a novel receptor analog of the invention.

The present invention supports a mechanism involving primarily steric hindrance for effecting  
35 trans-repression by a steroid hormone receptor or another receptor of the steroid/thyroid hormone receptor

superfamily, once the receptor is bound to a cognate recognition element in DNA associated with the promoter, the transcriptional activity of which is to be repressed.

The present invention is predicated upon the  
5 identification, isolation and characterization of the modular domains of receptors of the steroid/thyroid hormone receptor superfamily, which domains, particularly the C-terminal domain, may be modified, and the N-terminal domain all or partially removed, to create  
10 trans-acting transcription-repressing receptor analogs of the invention. We have discovered novel receptor analogs comprising a DNA-binding domain and a modified C-terminal domain, which novel receptors bind to a cognate response element of the DNA-binding domain and, apparently by  
15 steric hindrance in the vicinity of the response element, exhibit potent trans-acting transcription repression activity at a promoter operatively located from the response element for such transcription-repression to occur.

20 It has further been found that the DNA-binding domain is a necessary component in any receptor analog having such repressor activity, although the N-terminal, hypervariable region, is not essential for such repression. In fact, removal of all or part of the  
25 N-terminal domain advantageously enhances transcription-repressing activity and decreases transcription-activating activity. Thus, the receptor analogs employed in this invention contain a DNA-binding domain, optionally an N-terminal domain, and a C-terminal  
30 domain that is effective to provide (optionally upon ligand-binding) transcription repressing activity. The receptors analogs may be hybrid receptors wherein the DNA-binding domain, N-terminal domain (optional) and ligand-binding domain (C-terminal) are provided from  
35 receptors of different classes and/or species. For example, the C-terminus domain of the

glucocorticoid receptor, including the human glucocorticoid receptor, can be replaced herein by a portion of the C-terminus of the human mineralcorticoid receptor.

5       The present invention thus concerns a hormone or hormone-like receptor analog having trans-acting transcription repressor activity ("trans-repressing activity") with respect to a promoter with which it is associated, by virtue of the analog's ability to bind to  
10 a cognate response element in DNA upstream of said promoter and block the activity of other transcription factors associated with the promoter. A receptor analog of concern for the present invention, including the novel ones which per se are part of the present invention, can,  
15 like a corresponding native receptor, both repress transcription from promoters, whose transcription is repressed by the corresponding naturally occurring receptor, and activate transcription from promoters, whose transcription is activated by the corresponding  
20 native receptor. In the preferred receptor analogs, the trans-repressing activity is greater than that of the corresponding native (i.e., naturally occurring) receptor at the repressed promoters and the trans-activating activity is lower than that of the corresponding native  
25 receptor at the activated promoters.

      Thus, a novel receptor analog of the invention is a trans-repressing analog of a first receptor of the steroid/thyroid hormone superfamily of receptors, said analog comprising (1) a DNA-binding domain, through which  
30 the analog is capable of binding to a recognition element of said first receptor, when said recognition element is operatively associated with a promoter for trans-repression of the promoter by said first receptor;  
(2) a carboxy-terminal domain which is the carboxy  
35 terminal domain of a second receptor of the

steroid/thyroid hormone superfamily of receptors, said second receptor being different from said first receptor, or which is a polypeptide, which has less than about 60 % amino acid identity over its entire length, if shorter  
5 than the carboxy-terminal domain of said first receptor, or over any of its segments with the same length as the carboxy-terminal segment of said first receptor, provided that the polypeptide has about as many amino acids (at least about 90 % as many) as the carboxy-terminal domain  
10 of said first receptor; and (3) if the carboxy-terminal domain is the carboxy-terminal domain of a second receptor, an N-terminal domain that differs from the N-terminal domain of the first receptor by the deletion of a plurality of amino acids.

15 The present invention is further directed to the preparation of receptor analogs of the invention, and otherwise of concern for the methods of the invention, via recombinant DNA technology in all relevant aspects, including a DNA molecule that is a recombinant DNA  
20 molecule or a cDNA molecule consisting of a sequence encoding a receptor analog, and to requisite expression vectors harboring such DNA operatively for expression thereof and comprising expression control elements operative in the recombinant hosts selected for the  
25 expression, to recombinant host cells transfected with such operative expression vectors, and to transgenic, non-human animals, preferably mammals such as rats or mice, which harbor in some of their cells DNA from which a the receptor analog is expressed.

30 The invention is further directed to novel applications, described above, in various screening and therapeutic uses, of trans-repressing receptor analogs, DNAs that encode such analogs and from which the analogs can be expressed. particularly in mammalian cells, cells  
35 in which the analogs are expressed, and transgenic animals in some cells of which the analogs are expressed.



Thus, for example, the invention encompasses a novel, non-human transgenic mammal, which has symptoms of a disease due to inability to properly respond to a steroid or thyroid hormone, said animal having at least a  
5 subset of its cells in which are expressed an analog of a receptor for said hormone, said analog having trans-repression activity greater than that of said receptor and trans-activation activity less than that of said receptor.

10

### Detailed Description of the Invention

#### 1. Brief description of the drawings

Figure 1 is a dose response curve for hGR (human  
15 glucocorticoid receptor)-mediated repression of transcription. An hGR expression plasmid, wherein transcription of a cDNA encoding the hGR is driven by the rous sarcoma virus (RSV) promoter, was cotransfected into JEG-3 human placental cells (Akerblom *et al.*, *supra*),  
20 with a reporter plasmid in which transcription of DNA encoding CAT (cloramphenicol acetyltransferase), as the reporter or indicator protein, is driven by a transcription regulatory element which includes, from the regulatory element that controls transcription of the  
25 alpha168 glycoprotein hormone promoter, the DNA segment that includes the alpha168 glycoprotein hormone promoter and the glucocorticoid receptor response element (GRE), to which the naturally occurring hGR (when complexed with glucocorticoid hormone) binds. The co-transfection was by  
30 the calcium phosphate precipitation method. In different cultures, the ratio of hGR-encoding plasmid to reporter plasmid (referred to in the Figure as "promoter plasmid") used in the co-transfection was different. The total molar amount of RSV promoter DNA transfected was kept  
35 constant by replacing hGR-encoding plasmid with a control

plasmid, which was an RSV-promoter-containing expression plasmid, in which transcription of beta-galactosidase was driven by the RSV-promoter. The CAT activity from the reporter plasmid was measured as described in  
5 experimental procedures and normalized for transfection efficiency by dividing by the activity of beta-galactosidase provided by the control plasmid. Open circles indicate media without dexamethasone, solid circles media with  $10^{-7}$  M dexamethasone. In the  
10 particular experiment for which results are given in Figure 1, 2  $\mu$ g of reporter plasmid was used. The arrow indicates the ratio of receptor-encoding plasmid to reporter plasmid used in subsequent experiments.

Figure 2 presents the results of a scanning  
15 deletion analysis of the trans-repressing activity of hGR. Deletion mutants previously characterized for trans-activation (employing as a reporter plasmid one in which transcription of CAT is regulated by the hGR-responsive transcription regulatory segment  
20 (including promoter and GRE) of the mouse mammary tumor virus (MMTV)-LTR (Hollenberg *et al.*, *supra.*)), DNA binding and steroid binding were assayed on the alpha168 glycoprotein hormone transcription regulatory region (including the promoter and GRE) using the methods,  
25 reporter plasmids, RSV-promoter-containing control plasmid and cells described for Figure 1 and using expression plasmids for the hGR or mutants in which transcription of DNA encoding such proteins was driven by the RSV promoter. The wild type receptor (wt) (*i.e.*,  
30 naturally occurring receptor) comprises an immunogenic region (IMM), which coincides with the Taul region, a DNA binding domain (DNA), and a steroid-ligand binding domain (Steroid). The scale above the diagram of the wild-type receptor refers to amino acid number in the primary  
35 sequence of that receptor. Numbers to the left of the

diagrams of the various mutant receptors, when preceded by a delta, indicate amino acids immediately N-terminal and immediately C-terminal, respectively, of those deleted in the various mutants and, when accompanied by an asterisk (and, usually, preceded by an I), indicate the amino acid at which the mutant receptor is truncated. The mutant at the bottom of the Figure entails a deletion and a truncation. In the table to the right of the diagrams of the wt and mutant receptors, the relative activities of the receptors in trans-repression at the alpha168 transcription regulatory region ("repression") and trans-activation at the mouse mammary tumor virus LTR transcription regulatory region ("activation") are listed for both experiments in the presence of hormone (dexamethasone) and experiments in the absence of hormone. For each receptor mutant, relative activity in trans-repression is determined taking the CAT activity observed (normalized for transfection efficiency) using only RSV-promoter-containing control plasmid as representing 0 % activity in trans-repression and that observed using wild-type receptor as representing 100 % activity in trans-repression. The data in the table are +/- the standard error of the mean from the several experiments with each of the mutants. A single asterisk indicates trans-repression activity is less than 10 percent of wild type trans-repression activity on the alpha168 promoter. A double asterisk indicates less than 1 percent of trans-activation activity on the MMTV LTR promoter.

Figure 3 presents the results of a study, carried out by the methods described for Figure 2, of the trans-repression activity of mutants of the hGR in which an amino acid in the DNA-binding domain is changed to a glycine. The number of the changed amino acid in each of the mutants, in the primary sequence of the wild-type

hGR, is indicated in the table (Figure 3B) (with the prefix "G") along with the trans-repression activity (+/- the standard error of the mean of the results from the several experiments with the mutant) of the mutant with  
5 and without steroid (dexamethasone). In Figure 3B, an asterisk indicates less than 10 % of the trans-repression activity of the wild type hGR. (Wild-type hGR has no observable trans-repression or trans-activation activity in the absence of hormone.) The various mutants were  
10 previously assayed for trans-activation (Hollenberg and Evans, supra). In Figure 3A, solid circles indicate activities less than 10 percent of wild type and open circles indicated activities greater than 10 percent of wild type activity in the presence of dexamethasone. The  
15 boxed residue in Figure 3A represents the G442 mutant, which has a greater trans-repression activity than trans-activation activity. Bold residues in Figure 3A are those conserved throughout the steroid hormone receptor family.

20 Figure 4 represents the results of experiments on trans-repression and trans-activation activities of carboxy-terminal mutants of hGR. Such mutants include fusion proteins, with the carboxy-terminus of the wild-type hGR (by which is intended the part of the  
25 primary sequence of the receptor from amino acid 487 and higher, i.e., the part, including the ligand-binding domain, carboxy-terminal of the DNA-binding domain) replaced by a polypeptide of at least about 200 amino acids in length that, over the first 290 N-terminal amino  
30 acids, has less than about 60 % amino acid identity with amino acids 487 - 777 of the hGR (the carboxy-terminal domain). Trans-activation and trans-repression activities were measured by the methods described above for Figures 2 and 3, except that the RSV plasmid used in

controls 1 and 2 in place of the receptor- or receptor-analog-expressing plasmid had the thyroid hormone receptor-encoding cDNA inserted in the anti-sense orientation downstream of the RSV promoter rather than  
5 the beta-galactosidase-encoding DNA in the sense orientation (whereby beta-galactosidase was expressed). See Hollenberg et al., supra. The symbols in Figure 4, that also occur in Figure 2 or Figure 3, have the same meanings as in Figure 2 or Figure 3. Mutant I532  
10 beta-gal has the 1017 carboxy-terminal amino acids of beta-galactosidase from plasmid pBG-1, a derivative of plasmid pSK105 (Casadaban et al., Meth. Enzymol. 100, 293 (1983)), fused in-frame to amino acid 532 of hGR. hGR mutant GGM consists of amino acids 1 - 489 of hGR as the  
15 N-terminal part and amino acids 671 - 984 of hMR (human mineralocorticoid receptor) as the C-terminal part. Mutant GGM was made from a cDNA constructed by first introducing an additional XhoI site into both the hGR-encoding sequence at position 1596 (Hollenberg,  
20 Weinberger, Ong et al., Nature 318, 635 - 641 (1985)) and the hMR-encoding sequence at nucleotide position 2233 (Arriza, Weinberger, Cerelli, et al., Science, 237, 268 - 275. (1987)) and then inserting the appropriate XhoI  
25 puate XhoI site of the hGR-encoding sequence. With the wild-type hGR, control 1, and the three mutants other than GGM, the steroid used was dexamethasone. With the mutant with beta-gal at the carboxy-terminus, normalization for transfection efficiency was based on  
30 data from a plasmid in which luciferase was expressed from the RSV promoter, rather than the plasmid, described for Figure 1 supra, in which beta-galactosidase is expressed from the RSV promoter. With GGM and Control 2, the steroid used was aldosterone. Control 2 was the same  
35 as Control 1 except for the substitution of aldosterone for dexamethasone.

## 2. General methods and definitions

Amino acid identification is by the standard single- and three-letter abbreviations. All amino acids (except Gly) are L-amino acids:

5

Asp	D	Aspartic acid	Ile	I	Isoleucine
Thr	T	Threonine	Leu	L	Leucine
Ser	S	Serine	Tyr	Y	Tyrosine
Glu	E	Glutamic acid	Phe	F	Phenylalanine
Pro	P	Proline	His	H	Histidine
Gly	G	Glycine	Lys	K	Lysine
10 Ala	A	Alanine	Arg	R	Arginine
Cys	C	Cysteine	Trp	W	Tryptophan
Val	V	Valine	Gln	Q	Glutamine
Met	M	Methionine	Asn	N	Asparagine

A steroid receptor analog of is prepared by  
15 expression of DNAs encoding the receptor analog, in mature form, or precursors thereof, said DNAs being part of expression vectors prepared by conventional techniques and used conventionally to transform cells to make the receptor analog (including embryonic cells to provide  
20 transgenic animals, at least some subset of cells of which make the receptor analog). A precursor of the receptor analog may 1) have methionine as the first amino acid (present by virtue of the ATG encoding the translational start signal in the DNA encoding the  
25 precursor) or 2) have a signal polypeptide or conjugated protein other than a signal polypeptide. As understood in the art, the methionine, signal peptide or conjugated protein other than a signal peptide is cleaved to yield the mature receptor analog. In all events, the thus  
30 produced mature receptor analog is either left, and used, inside the cell in which it is expressed or is recovered from the cell and purified to a level suitable for intended extracellular use.

The "hormone or hormone-like receptor analogs" of  
35 this invention or used in the methods of this invention

include analogs of receptors of the steroid/thyroid hormone superfamily of receptors, including, among others, the glucocorticoid, mineralocorticoid, estrogen, progesterone, thyroid hormone, retinoic acid, and vitamin D3 receptors including such receptors from all species, including, among others, mammalian, including the human, species.

"Expression vector" means a vector which is capable of effecting expression of a DNA sequence contained in the vector once the vector has been transfected, transformed, microinjected or otherwise introduced into a suitable cell. In an expression vector, the DNA sequence to be expressed is operatively linked to other sequences capable of effecting the transcription of the DNA sequence along with other sequences, such that the transcript of the DNA sequence can be productively translated. A "suitable cell" for the vector is one in which these other, transcription-effecting sequences and the resulting translation-effecting sequences are recognized for transcription and translation. Construction of an expression vector of the invention and for use in accordance with the present invention is well within the skill of the person of ordinary skill in molecular biology, as are methods of introducing such a vector into cells suitable for expression of the DNA sequence intended to be expressed with the vector. An expression vector, in a suitable cell in which the vector is operative, can function as an episome or can be integrated into genomic DNA of the cell. An expression vector can be a circularized plasmid, a linearized plasmid or a part thereof, or all or part of a viral genome. Preferred for the present invention are expression vectors that are operative to effect expression of a DNA sequence in mammalian cells.

"Operative," or grammatical equivalents, for a particular purpose means, or refers to, means that are

functional for the purpose. Thus, for example, "operatively linked for transcription" means linked by means (a DNA segment) that is functional in allowing transcription to occur.

5 "Recombinant host cells" refers to cells into which an expression vector, which will have been constructed by recombinant DNA methods, for a protein has been introduced by transfection, transformation, infection, microinjection or the like, or the progeny of  
10 such a cell which retain DNA that is capable of functioning to effect the expression of the protein.

Preparation of recombinant host cells and transgenic animals using expression vectors, from which receptor analogs of concern for the present invention are  
15 expressed, is well within the skill of those of ordinary skill in the art, as is the use of such cells and animals in screening compounds or other compositions for the purposes described hereinabove.

"Extrinsic support medium" includes those known or  
20 devised media that can support cells in a growth phase or maintain them in a viable state such that they can produce protein from DNA introduced using an expression vector (*i.e.*, perform their "recombinantly harnessed function.") See, for example, ATCC Media Handbook,  
25 American Type Culture Collection, Rockville, MD (1984 and later editions).

In addition to the above discussion and the various references to existing teachings in the art, reference is made to standard textbooks of molecular biology that  
30 contain definitions and methods and means for carrying out basic techniques in connection with the present invention. See, for example, Maniatis, et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, New York, 1982 and the various references  
35 cited therein; Sambrook et al., Molecular Cloning: A Laboratory Manual (2nd Ed.), Cold Spring Harbor



Laboratory, New York, 1989 and the various references cited therein; and Colowick et al., Methods in Enzymology Vol 152, Academic Press, Inc., New York, New York (1987). All of the herein cited publications are  
5 incorporated herein by reference.

The description, including the following experimental details, in the present specification is intended to teach the invention and how to carry it out but not to limit the scope of the invention. It is understood, for  
10 example, that the skilled will readily recognize that they could employ different combinations of techniques, including techniques which the present inventors have not employed or described explicitly herein, to accomplish the same ends. Thus, for example, the skilled may  
15 synthesize the underlying DNA sequences encoding a particular novel receptor analog hereof for deployment within similar or other suitable, operative expression vectors and culture systems. Further, the skilled will readily recognize that they could apply the teaching of  
20 the present specification with analogs of receptors other than the human glucocorticoid receptor, which the present inventors elected to study as a prototype or model in making the present invention. The skilled will recognize that the present inventors, with their teaching herein,  
25 based on their discovery and elucidation, with analogs of the human glucocorticoid receptor as models, of the location, composition and mode of action in trans-repression, of domains involved in trans-repression, have provided a broad teaching of trans-repressing analogs of  
30 receptors of the steroid/thyroid hormone superfamily generally, including analogs in which domains from different members of the superfamily are combined, with or without modification.

3. Detailed description of various embodiments

The present invention was premised upon use of the glucocorticoid receptor as a prototypical model, for the elucidation of the trans-repressing activity of receptors  
5 of the steroid/thyroid hormone superfamily of receptors, including glucocorticoid, mineralocorticoid, estrogen, progesterone, thyroid hormone-alpha, thyroid hormone-beta, retinoic acid, and vitamin D3 receptors, and for the identification, based on such elucidation, of  
10 trans-repressing analogs, including certain novel analogs, of such receptors. Particularly sought were trans-repressing analogs that have trans-repressing activity (measured relative to that of the corresponding native ("wild-type") receptor) that is greater than  
15 trans-activating activity (also measured relative to that of the corresponding native receptor), and especially analogs in which the trans-repressing activity is increased relative to that of the native receptor and the trans-activating activity is decreased relative to that  
20 of the native receptor. These especially preferred analogs can confer on a cell in which they are expressed the phenotype in which the function of the hormone corresponding to the native receptor is dominantly repressed.

25 The present specification teaches those of ordinary skill how to identify readily trans-repressing analogs of such receptors, including such analogs with the more desirable properties.

As outlined, supra, analogs with trans-repressing  
30 activity greater than trans-activating activity, and especially those with trans-repressing activity increased over, and trans-activating activity reduced below, that of the corresponding native receptor, may be especially usefully employed in gene therapy, to remedy a disease  
35 due inability to properly process the hormone of the

corresponding native receptor, and in screening, with cells in culture or transgenic animals, for compositions effective to treat diseases due to inability to properly process the hormone of the corresponding native  
5 receptor. In the latter application, transgenic rodents, and especially transgenic mice, are especially preferred. Among such diseases that may be remedied, or for which therapeutically effective compositions may be identified, in accordance with these novel methods of use  
10 of the present invention, novel cells of the invention, and novel, non-human transgenic animals of the invention, are various disorders, including manic depressive disorders, immune system disorders, and growth-related disorders, due to the inability to properly process  
15 glucocorticoids; pseudohypoaldosteronism, characterized by inability to properly process aldosterone; and erythroblastoid leukemias and the various manifestations of Cretinism, which are due to the inability of cells to properly process thyroid hormone.

20

#### 4. Examples

Certain experimental details are described above, in connection with description of the Figures, and are not repeated here.

25

##### Recombinant Plasmids

I515\* GR (glucocorticoid receptor) and delta-77-262 GR are prepared as described by Hollenberg et al., Cell 49, 39 (1987).

30

Mutant delta-77-262, I515\* GR was made by swapping the ClaI-XhoI fragment of the mutant I515\* with that of delta-77-262 GR mutant.

The construction of the alpha168CAT, with the alpha168 glycoprotein hormone promoter and associated  
35 regulatory elements including a GRE, driving expression

of CAT, has been described by Delegeane et al., Mol. Cell Bio 7, 3994 (1987)).

#### Transfections and Reporter Assays

5 JEG-3 human placental cells were maintained in DMEM (Dulbecco's Modified Eagles' Medium), 10 percent defined calf bovine serum (CBS), and 0.4 percent glucose and split 24 hours prior to transfection into 5 percent CBS charcoal-stripped serum plus glucose (Akerblom et al.,  
10 Science 241, 350 (1988)). Transfections were performed in JEG-3 cells via the calcium phosphate precipitation method (Delegeane et al., supra (1987)). Typically, 2 µg of reporter and 4 µg of receptor plasmid were used along with 2 µg of RSV β-gal (Hollenberg et al., supra (1987))  
15 as an internal control for transfection efficiency. Dexamethasone and aldosterone ( $10^{-7}$  M) were added after calcium phosphate treatment. CAT assays were performed according to Hollenberg et al., supra (1987), but with 25 µg total cell extract protein for 3 hours or less. TLC  
20 plates were cut and counted in Econofluor +5 percent DMSO. Luciferase and beta-galactosidase, produced from plasmids used to provide data for normalization for transfection efficiency, were assayed by standard methods.

25

#### hGR Trans-repression

To characterize the hGR-mediated repression, a dose response curve was performed of hGR expression plasmid for negative regulation of the alpha 168 CAT expression  
30 in human placental JEG-3 cells. Varying amounts of the hGR expression plasmid and alpha168 CAT plasmid were cotransfected, and the resultant transient CAT activity plus and minus dexamethasone was measured. Throughout the experiment the total amount of RSV promoter was  
35 constant, thus controlling for possible titration of

transcription factors by RSV DNA. Figure 1 shows the hormone-dependent reduction in gene expression with the transfection of exogenous receptor cDNA into cells with the alpha168 glycoprotein hormone transcription  
5 regulatory apparatus.

Increasing amounts of the receptor expression plasmid yielded a correspondingly higher steroid-dependent repression of transcription from the alpha168 promoter. In the absence of receptor cDNA, less  
10 than 10 percent of maximal repression can be measured. Beginning at a receptor to promoter ratio of 1 and continuing to a ratio of 5, a plateau of repression activity emerged where more receptor plasmid yielded no additional steroid-dependent repression. Since the  
15 amount of RSV promoter was held constant, this plateau indicates probable saturation of the site of receptor action. For subsequent experiments, for which results are presented in the Figures, a receptor to promoter ratio of 2:1 was used. The steroid-dependent repression  
20 of alpha168 reporter observed with wild-type hGR varies between 6 and 20 fold with an average of 9 fold as typified in Figure 1. This assay can reliably measures as low as 10 percent of wild type hGR repression.

## 25 Distinct Activation and Repression Domains

Various hGR mutants were tested in the repression assay and compared to their activities in the MTV activation assay. Figure 2 shows a comparison of repression activity by various hGR mutants on the  
30 alpha168 promoter compared to activation on the MTV promoter. Deletions in the amino terminus (i.e., the part of the native receptor that is in the amino-terminal direction from the amino-terminus of the DNA-binding domain or, in the case of hGR, the part of the mature  
35 receptor from amino acids 1 - 420) had no adverse effect

on repression activity. In fact, amino-terminal mutants, including those lacking up to 376 amino terminal residues, displayed increased dexamethasone-dependent repression in comparison with the native receptor and  
5 unchanged, or marginally increased, repression activity with mutant receptors which retain transcription-altering activity but are altered outside the N-terminal domain. For example, deletion of the trans-activation-related sequence Taul (amino acids 78-261), that roughly  
10 coincides with the immunogenic region (IMM), in the mutant designated delta-77-262, increases trans-repression activity to 140 percent of wild type activity while dramatically reducing trans-activation activity at the MTV promoter to 10 percent of wild-type. Compare  
15 also mutant delta-77-262, I515\* (the bottom entry in Figure 2) with mutant I515\*. These results demonstrate that the amino terminus of a receptor of the steroid/thyroid hormone receptor superfamily (i.e., the part of the receptor N-terminal from the N-terminus of  
20 its DNA-binding domain) plays reciprocal roles in repression and activation and that receptor analogs that differ from the corresponding native receptor or mutants thereof only in a deletion in the amino-terminus will have at least the same trans-repressing activity as the  
25 corresponding native receptor or mutant, on a promoter which is trans-repressed by the native receptor or mutant, and will have significantly reduced trans-activation activity on a promoter, which is trans-activated by the native receptor or mutant.

30

#### DNA-Binding Domain Required for Repression Activity

The DNA-binding domain of the hGR is cysteine-rich and has been proposed to be comprised of two zinc fingers, as described supra. The presence the  
35 DNA-binding domain is necessary since insertions in or

deletions from this region (mutants delta-420-451 (missing amino acids 421 - 450, the first zinc-finger), delta-450-487 (missing amino acids 451 - 486, the second zinc-finger), and delta-428-490 (missing amino acids 429  
5 - 489, most of the DNA-binding domain)(Figure 2) yield receptor variants that are incapable of both trans-repression and trans-activation. Both zinc fingers are required for trans-repression as well as trans-activation.

10 Nineteen (19) receptor variants, each harboring one amino acid change (a glycine for the numbered amino acid) in the DNA-binding domain, were comparatively evaluated for their trans-repressor and trans-activator activities (Figure 3). Most of the mutants have corresponding  
15 effects on both repression and activation. For example, mutants in residues 480 and 431, (labeled G480 and G431, respectively), reduce both repression and activation to 70 percent of their wild type values while G438 and G445 eliminate both activities. 18 of the 19 mutants show  
20 parallel effects on activation and repression. In contrast, one mutant, G442, retains 68 percent of full repressor function while it activates only 1 percent. Moreover, this lysine-to-glycine mutant binds hormone and DNA in vitro with nearly normal activity. Apparently, it  
25 is the retention of its DNA-binding capacity that allows the mutant to remain active in trans-repression although transactivation requires, in addition to DNA binding, a function lost in the mutant.

### 30 Carboxyl Terminus Enhances Repression

Truncation deletion-mutants reveal that the carboxyl terminus (the part of the receptor carboxy-terminal from the carboxy-terminal end of the DNA-binding domain) plays an important role in both  
35 negative regulation (i.e., trans-repression) and

activation (i.e., trans-activation). The carboxy-terminal part of an hormone or hormon-like receptor of the steroid/thyroid hormone superfamily has two sub-domains: the ligand-binding subdomain and an  
5 "hinge-subdomain," which joins the carboxy-terminus of the DNA-binding domain to the amino-terminus of the ligand-binding domain. The following Table 5 lists the approximate boundaries of these sub-domains for representatives of this superfamily of receptors:

10

Table 5

Receptor	First Amino Acid of Hinge Subdomain	First Amino Acid of Ligand-binding Subdomain
15 Human Glucocorticoid	487	528
Human Mineralocorticoid	669	734
Human Thyroid Hormone Beta	169	232
(c-erbA gene protein)		
Rat Neuronal Thyroid	120	183
Hormone (Alpha)		
Human Estrogen	251	311
20 Rabbit Progesterone	634	680
Human Retinoic Acid	154	198
Human Vitamin D3	90	192

With reespect to the data in Table 5, see the published patent applications cited at the beginning of the present specification.

25

Several receptors of the steroid/thyroid hormone superfamily are known to have subsegments, that are apparently not related to ligand-binding and are located carboxy-terminal of the carboxy-terminal end of the ligand-binding subdomain. However, for purposes of the  
30 present specification, these additional subsegments are deemed to be part of the ligand-binding subdomain of the carboxy-terminal domain. In this regard, also see the published patent applications cited at the beginning of this specification.

35



As shown in Figure 2, mutant I490\* truncates the receptor at amino acid 490 adjacent to the DNA binding domain and has lost both repressor and activator functions. Deletions or truncation that intrude on the ligand-binding domain (for example, delta-515-551, delta-490-583, I582\* in Figure 4) eliminate DNA and hormone binding and also completely eliminate both activities. In contrast, deletions in the region linking the DNA binding and ligand binding domains (delta-490-515) retain near wild-type, steroid-dependent repression and activation. Further, truncation mutants I550\* and I532\* remove the entire ligand binding domain and engender analogs that are both constitutive (i.e., ligand-independent) repressors and activators. Truncation mutant I550\* reduces the repression to 30 percent of wild type with I532\* retaining only marginal repressor function. These results suggest the requirement of an intact ligand binding subdomain and at least about the 10 carboxy-terminal amino acids of the hinge subdomain for retention of most (i.e., more than about 50 % of wild-type) of trans-repression and trans-activation activities and localize an important domain for trans-repression activity to the carboxyl terminal amino acids of receptors of the steroid/thyroid hormone superfamily.

#### Fusion Repressors

At least two mechanisms exist to explain the role of the carboxyl-terminus in trans-repression. First, a particular region of the carboxyl terminus could interact specifically with an activator to block or mask transactivation properties and thereby effect trans-repression. Secondly, the carboxyl terminus could mediate its effects by steric hindrance as has been shown in procaryotic systems, blocking the interaction of

transcription factors near their sites of action on DNA or the interaction of cooperatively acting proteins with each other.

Novel sequence specific repressors were created by  
5 attaching heterologous protein sequences to the carboxyl  
terminal side of the hGR DNA binding domain. In the  
first case, the hinge and ligand binding subdomains of a  
related steroid receptor (hMR) was substituted for the  
homologous region of the hGR. This hybrid receptor, as  
10 shown in Figure 4, becomes an aldosterone-dependent  
activator of the MTV promoter and an aldosterone-  
dependent repressor of the alpha 168 promoter. Thus, the  
hMR carboxyl terminus is able to substitute for both  
activator and repressor functions. Although aldosterone  
15 is not known to naturally influence the expression of the  
alpha168 promoter, one could argue that the amino acid  
homology of these steroid receptors represents  
evolutionary selection for several functions including  
trans-repression. To address this possibility, *E. coli*  
20  $\beta$ -galactosidase ( $\beta$ -gal) was fused in frame to the  
carboxyl terminal side of the hGR DNA-binding domain and  
assayed for regulatory properties. On the MTV promoter  
this hybrid functions as a constitutive activator with  
properties unchanged from that of the parental truncated  
25 receptor (I532\*). On the alpha168 promoter, the fusion  
protein is a constitutive repressor whose activity is  
dramatically increased when compared to that of I532\*.  
Thus, the addition of a heterologous *E. coli* protein  
sequence to the DNA binding domain of the hGR is  
30 sufficient for generation of a functional transcriptional  
repressor.

Our data show that activation and repression by hGR  
share some common features. First, the results  
demonstrate a requirement for the DNA-binding domain in  
35 hGR-mediated repression. This reflects the fact that

both positive and negative regulation are DNA sequence-specific. The result that 18 out of 19 point mutations in this region affect repression and activation equivalently argues that this domain is serving a common function in each process. Further, because many of these 18 mutations affect DNA-binding, we deduce that the same amino acids are critical for recognition of response elements mediating both activation and repression. Secondly, the carboxyl terminal deletions show that activation and repression at near wild-type levels require an intact ligand binding domain and the presence of hormone. Removal or replacement of this region by heterologous sequences leads to hormone independence for both processes.

In contrast, the results of this study provide several criteria that distinguish positive and negative regulatory effects of the hGR. First, the amino terminal domain that contains a potent activator sequence (Tau 1) is not necessary for trans-repression. This fact substantiates the duality of receptor function and is highlighted by the observation that deletion of Tau 1 engenders a more potent repressor. This argues that even when functioning as a repressor, the amino terminal region of the hGR retains some residual activating activity.

The DNA-binding domain mutation, G442, establishes a second criterion distinguishing the two processes. The mutation produces a receptor that retains significant trans-repression activity but has lost virtually all trans-activation capability. This result demonstrates that the process of activation can be mechanistically distinguished from that of repression and that the function of the DNA-binding domain is more than simply to locate an appropriate regulatory sequence. Moreover, the result also implies that activation requires an

additional event subsequent to DNA-binding that is apparently not critical for repression.

A third criterion differentiating activation and repression is that a  $\beta$ -galactosidase moiety functionally replaces the hR carboxyl terminus only in repression. Removal of the ligand-binding subdomain results in a receptor variant with minimal repression activity. The role of this region might be explained by two models. First, it might directly interact with other transcription factors to block or neutralize their transactivation domains. Secondly, it might non-specifically inhibit activation by preventing other factors from binding to DNA or interacting with the transcription machinery. The latter steric hindrance model is supported by the fact that addition of a  $\beta$ -galactosidase moiety selectively increases repression and not activation, while addition of an hMR carboxyl terminus increases both activities. Given the lack of amino acid identity or similar charge distribution between the hGR, hMR and  $\beta$ -gal, a role for specific interaction with another transcription factor is unlikely. A reasonable property conserved between the carboxyl termini of hGR and the two fusion proteins is relative size. I532\* lacks 245 carboxyl terminal amino acids of the wild type hGR, whereas the hGR-hMR and the hGR- $\beta$ -gal fusions add 310 and 1030 amino acids, respectively. In contrast to previously characterized trans-activation or trans-repression domains where charge distribution or a conserved amino acid sequence is important, hGR trans-repression domains appear to require molecular volume.

Any process which requires the proximity of two transcription factors can be repressed by steric hindrance. On the  $\alpha$ 168 promoter, basal expression requires both CRE and TSE binding proteins as well as

factors binding to CCAAT and TATA sequences (Akerblom et al., 1988, supra). The displacement or prevention of any of these proteins bound to their elements would reduce transcription. The footprinted hGR binding sites cover  
5 the TSE/CRE border and support an interaction between the hGR, and the TSE and CRE binding proteins; lack of the TSE drops basal expression 8-10 fold (e.g., the 152-100 tk cat promoter construction (Akerblom et al., 1988, supra)), and reduces basal level hGR-mediated repression.  
10 It is possible to create fusion repressors because the DNA-binding domain, and other domains associated with trans-activation and trans-repression, are functionally largely independent and structurally distinct. These results suggest a general strategy to produce sequence-  
15 specific transcription repressors, with the sequence specificity provided by a DNA-binding domain.

The fact that the foregoing description is somewhat detailed should not be construed as limiting the overall  
20 scope hereof; rather, the ambit of the present invention is to be governed only by the lawful construction of the appended claims.

25

30

35

CLAIMS:

1. A trans-repressing analog of a first receptor of the steroid/thyroid hormone superfamily of receptors,  
5 said analog comprising (1) a DNA-binding domain, through which the analog is capable of binding to a recognition element of said first receptor, when said recognition element is operatively associated with a promoter for trans-repression of the promoter by said first receptor;  
10 (2) a carboxy-terminal domain which is the carboxy terminal domain of a second receptor of the steroid/thyroid hormone superfamily of receptors, said second receptor being different from said first receptor, or which is a polypeptide, which has less than about 60 %  
15 amino acid identity over its entire length, if shorter than the carboxy-terminal domain of said first receptor, or over any of its segments with the same length as the carboxy-terminal segment of said first receptor, provided that the polypeptide has about as many amino acids as the  
20 carboxy-terminal domain of said first receptor; and (3) if the carboxy-terminal domain is the carboxy-terminal domain of a second receptor, an N-terminal domain that differs from the N-terminal domain of the first receptor by the deletion of a plurality of amino acids.
- 25 2. A receptor analog of Claim 1 which is an analog of a glucocorticoid receptor.
3. A receptor analog of Claim 2 which is selected from the group consisting of I532-betaGal and analogs of GGM, wherein the N-terminal domain is the same as that of  
30 an analog selected from the group consisting of delta77-262, delta262-404, delta9-385, and the analog in which amino acids 1 - 420 are deleted.
4. A receptor analog according to Claim 1 wherein the C-terminal domain is amino acids 8 - 1025 of  
35 beta-galactosidase.

5. An expression vector capable of expressing a receptor analog according to any of Claims 1 - 4.

6. A recombinant host cell transfected with an expression vector according to Claim 5.

5 7. A cell culture comprising cells according to Claim 6 and an extrinsic support medium assuring the viability of said cells.

8. A non-human transgenic mammal, which has symptoms of a disease due to inability to properly  
10 respond to a steroid or thyroid hormone, said animal having at least a subset of its cells in which are expressed an analog of a receptor for said hormone, said analog having trans-repression activity greater than that of said receptor and trans-activation activity less than  
15 that of said receptor.


9. A mammal according to Claim 8, wherein the hormone is selected from the group consisting of a glucocorticoid hormone, aldosterone, and a thyroid hormone.

20 10. A mammal according to Claim 9, wherein the hormone is a glucocorticoid hormone and the receptor analog is selected from the group consisting of delta77-262, delta262-404, delta9-385, and the human glucocorticoid receptor analog in which amino acids 1 -  
25 420 are deleted.


11. A mammal according to any of Claims 8 - 10 which is a mouse.

30


35








α168 CAT		MTV	
REPRESSION	ACTIVATION		
-DEX	+DEX	-DEX	+DEX
*	100	**	100
*	140 ± 10	**	10
*	195 ± 95	**	85
*	160 ± 18	**	10
*	*	**	**
*	*	**	**
*	*	**	**
*	74 ± 11	**	95
*	*	**	**
*	*	**	**
*	*	**	**
*	*	**	**
22 ± 8	22 ± 8	10	10
11 ± 2	11 ± 2	10	10
31 ± 6	31 ± 6	40	40
24 ± 6	24 ± 6	1	1



**FIG. 3B**

Glycine Mutant	%wt Repression		Glycine Mutant	%wt Repression	
	-DEX	+DEX		-DEX	+DEX
G421	*	*	G457	*	*
G423	*	*	G463	*	*
G424	*	*	G470	*	*
G426	*	56±3	G471	*	13±3
G431	*	79±21	G473	*	*
G432	*	*	G476	*	*
G438	*	*	G477	*	*
G441	*	*	G480	*	*
G442	*	68±12	G481	*	70±1
G445	*	*			

FIG. 4



$\alpha$ 168 Repression		MTV Activation	
-Steroid	+Steroid	-Steroid	+Steroid
*	*	**	**
*	100	**	100
*	*	**	**
11 $\pm$ 2	11 $\pm$ 2	15	15
62 $\pm$ 7	62 $\pm$ 7	10	10
*	60 $\pm$ 7	**	150
*	*	**	**

# INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US89/05859**

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) *		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC (5) : C07H 15/12; C12N 5/00; G02F 1/11; C12N 15/00 U.S. Cl : 536/27; 435/320; 435/240.1; 800/2; 935/33		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
U.S.	536/27; 350/358; 800/2; 935/33 435/320; 435/240.1	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
APS, CAS, BIOSIS		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b>		
Category *	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
<u>X</u> Y	Nature, Volume 325 issued January 1987; Green et al. "Oestradiol induction of a glucocorticoid-responsive gene by a chimeric receptor" pages 75-78. See abstract.	<u>1,2,5,6,7</u> 3,4,8-11
Y	Cell, Volume 55 issued 02 December 1988; Hollenberg et al. "Multiple and Cooperative Trans-Activation Domains of the Human Glucocorticoid Receptor" pages 899-906. See abstract.	1-11
Y	Cell, Volume 51 issued December 1987; Kumar et al. "Functional Domains of the Human Estrogen Receptor" pages 941-951. See abstract.	1-11
Y	Cell, Volume 49 issued April 1987; Hollenberg et al. "Colocalization of DNA-Binding and Transcriptional Activation Functions in the Human Glucocorticoid Receptor" pages 39-46. See abstract.	1-11
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>* Special categories of cited documents: <sup>10</sup></p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p> </div> </div>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search		Date of Mailing of this International Search Report
06 April 1990		<b>21 MAY 1990</b>
International Searching Authority		Signature of Authorized Officer - Robert A. Wax
ISA/US		

## FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

Y

WO 88/03168 (Salk Institute for Biological  
Studies) 05 May 1988. See pages 20,22 and 78.

1-11

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE<sup>1</sup>

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers \_\_\_\_\_, because they relate to subject matter <sup>12</sup> not required to be searched by this Authority, namely:
2. ☐ Claim numbers \_\_\_\_\_, because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out <sup>13</sup>, specifically:
3. ☐ Claim numbers \_\_\_\_\_, because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING<sup>2</sup>

This International Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.
2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:
3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:
4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority <sup>3</sup> invite payment of any additional fee.

## Remark on Protest

- ☐ The additional search fees were accompanied by applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.